Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

Background & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to...

Descripción completa

Detalles Bibliográficos
Autores: Garcia Garcia de Paredes, Ana|||0000-0001-5498-6280, Villanueva, Càndid|||0000-0002-3674-914X, Blanco, Carolina, Genescà Ferrer, Joan|||0000-0002-0831-8422, Manicardi, Nicolo, García-Pagán, JC.|||0000-0001-9032-4954, Calleja, Jose Luis|||0000-0002-2265-6591, Aracil, Carlos|||0000-0002-8228-9041, Morillas Cunill, Rosa Ma|||0000-0001-9117-5049, Poca Sans, Maria|||0000-0002-0235-1395, Peñas, Beatriz, Augustin Recio, Salvador|||0000-0002-3515-9033, Abraldes, Juan G.|||0000-0003-3421-937X, Alvarado-Tapias, Edilmar|||0000-0003-2036-6133, Royo, Félix, García-Bermejo, Mª Laura, Falcón-Pérez, Juan M.|||0000-0003-3133-0670, Bañares, Rafael|||0000-0002-0412-8437, Bosch, Jaime|||0000-0003-3414-0055, Gracia-Sancho, Jordi|||0000-0001-7736-4089, Albillos, Agustín|||0000-0001-9131-2592
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:270216
Acceso en línea:https://ddd.uab.cat/record/270216
https://dx.doi.org/urn:doi:10.1016/j.jhepr.2021.100368
Access Level:acceso abierto
Palabra clave:Ascites
Beta-blockers
Cirrhosis
MicroRNA
Portal hypertension
id ES_73a9d305ce514b5ed665115f4856958a
oai_identifier_str oai:ddd.uab.cat:270216
network_acronym_str ES
network_name_str España
repository_id_str
spelling Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosisGarcia Garcia de Paredes, Ana|||0000-0001-5498-6280Villanueva, Càndid|||0000-0002-3674-914XBlanco, CarolinaGenescà Ferrer, Joan|||0000-0002-0831-8422Manicardi, NicoloGarcía-Pagán, JC.|||0000-0001-9032-4954Calleja, Jose Luis|||0000-0002-2265-6591Aracil, Carlos|||0000-0002-8228-9041Morillas Cunill, Rosa Ma|||0000-0001-9117-5049Poca Sans, Maria|||0000-0002-0235-1395Peñas, BeatrizAugustin Recio, Salvador|||0000-0002-3515-9033Abraldes, Juan G.|||0000-0003-3421-937XAlvarado-Tapias, Edilmar|||0000-0003-2036-6133Royo, FélixGarcía-Bermejo, Mª LauraFalcón-Pérez, Juan M.|||0000-0003-3133-0670Bañares, Rafael|||0000-0002-0412-8437Bosch, Jaime|||0000-0003-3414-0055Gracia-Sancho, Jordi|||0000-0001-7736-4089Albillos, Agustín|||0000-0001-9131-2592AscitesBeta-blockersCirrhosisMicroRNAPortal hypertensionBackground & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to NSBBs in compensated cirrhosis. Methods: Serum levels of miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p were analyzed in patients with compensated cirrhosis (N = 105). Hepatic venous pressure gradient (HVPG) was measured at baseline, after intravenous propranolol, and 1 year after randomization to NSBBs (n = 52) or placebo (n = 53) (PREDESCI trial). miRNAs were analyzed at baseline and at 1 year. Results: Nineteen patients (18%) developed ascites, of whom 17 developed ascites after 1 year. miR-181b-5p levels at 1 year, but not at baseline, were higher in patients that developed ascites. The AUC of miR-181b-5p at 1 year to predict ascites was 0.7 (95% CI 0.59-0.78). miR-429 levels were lower at baseline in acute HVPG responders to NSBBs (AUC 0.65; 95% CI, 0.53-0.76), but levels at baseline and at 1 year were not associated with the HVPG response to NSBBs at 1 year. Conclusions: Serum miR-181b-5p is a promising non-invasive biomarker to identify patients with compensated cirrhosis at risk of ascites development. Lay summary: Ascites marks the transition from the compensated to decompensated stage in cirrhosis and indicates a worsening in prognosis. There are currently no easily accessible tools to identify patients with compensated cirrhosis at risk of developing ascites. We evaluated the levels of novel molecules termed microRNAs in the blood of patients with compensated cirrhosis and observed that miR-181b-5p can predict which patients are going to develop ascites.Universitat Autònoma de Barcelona 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/270216https://dx.doi.org/urn:doi:10.1016/j.jhepr.2021.100368reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 SAF2017-86343-RInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI20/01302Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/01901Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 CIBEREHD-16PI03Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI20/00220Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 CM18/00091open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2702162026-06-06T12:50:31Z
dc.title.none.fl_str_mv Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
title Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
spellingShingle Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
Garcia Garcia de Paredes, Ana|||0000-0001-5498-6280
Ascites
Beta-blockers
Cirrhosis
MicroRNA
Portal hypertension
title_short Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
title_full Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
title_fullStr Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
title_full_unstemmed Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
title_sort Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis
dc.creator.none.fl_str_mv Garcia Garcia de Paredes, Ana|||0000-0001-5498-6280
Villanueva, Càndid|||0000-0002-3674-914X
Blanco, Carolina
Genescà Ferrer, Joan|||0000-0002-0831-8422
Manicardi, Nicolo
García-Pagán, JC.|||0000-0001-9032-4954
Calleja, Jose Luis|||0000-0002-2265-6591
Aracil, Carlos|||0000-0002-8228-9041
Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
Poca Sans, Maria|||0000-0002-0235-1395
Peñas, Beatriz
Augustin Recio, Salvador|||0000-0002-3515-9033
Abraldes, Juan G.|||0000-0003-3421-937X
Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
Royo, Félix
García-Bermejo, Mª Laura
Falcón-Pérez, Juan M.|||0000-0003-3133-0670
Bañares, Rafael|||0000-0002-0412-8437
Bosch, Jaime|||0000-0003-3414-0055
Gracia-Sancho, Jordi|||0000-0001-7736-4089
Albillos, Agustín|||0000-0001-9131-2592
author Garcia Garcia de Paredes, Ana|||0000-0001-5498-6280
author_facet Garcia Garcia de Paredes, Ana|||0000-0001-5498-6280
Villanueva, Càndid|||0000-0002-3674-914X
Blanco, Carolina
Genescà Ferrer, Joan|||0000-0002-0831-8422
Manicardi, Nicolo
García-Pagán, JC.|||0000-0001-9032-4954
Calleja, Jose Luis|||0000-0002-2265-6591
Aracil, Carlos|||0000-0002-8228-9041
Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
Poca Sans, Maria|||0000-0002-0235-1395
Peñas, Beatriz
Augustin Recio, Salvador|||0000-0002-3515-9033
Abraldes, Juan G.|||0000-0003-3421-937X
Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
Royo, Félix
García-Bermejo, Mª Laura
Falcón-Pérez, Juan M.|||0000-0003-3133-0670
Bañares, Rafael|||0000-0002-0412-8437
Bosch, Jaime|||0000-0003-3414-0055
Gracia-Sancho, Jordi|||0000-0001-7736-4089
Albillos, Agustín|||0000-0001-9131-2592
author_role author
author2 Villanueva, Càndid|||0000-0002-3674-914X
Blanco, Carolina
Genescà Ferrer, Joan|||0000-0002-0831-8422
Manicardi, Nicolo
García-Pagán, JC.|||0000-0001-9032-4954
Calleja, Jose Luis|||0000-0002-2265-6591
Aracil, Carlos|||0000-0002-8228-9041
Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
Poca Sans, Maria|||0000-0002-0235-1395
Peñas, Beatriz
Augustin Recio, Salvador|||0000-0002-3515-9033
Abraldes, Juan G.|||0000-0003-3421-937X
Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
Royo, Félix
García-Bermejo, Mª Laura
Falcón-Pérez, Juan M.|||0000-0003-3133-0670
Bañares, Rafael|||0000-0002-0412-8437
Bosch, Jaime|||0000-0003-3414-0055
Gracia-Sancho, Jordi|||0000-0001-7736-4089
Albillos, Agustín|||0000-0001-9131-2592
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Ascites
Beta-blockers
Cirrhosis
MicroRNA
Portal hypertension
topic Ascites
Beta-blockers
Cirrhosis
MicroRNA
Portal hypertension
description Background & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to NSBBs in compensated cirrhosis. Methods: Serum levels of miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p were analyzed in patients with compensated cirrhosis (N = 105). Hepatic venous pressure gradient (HVPG) was measured at baseline, after intravenous propranolol, and 1 year after randomization to NSBBs (n = 52) or placebo (n = 53) (PREDESCI trial). miRNAs were analyzed at baseline and at 1 year. Results: Nineteen patients (18%) developed ascites, of whom 17 developed ascites after 1 year. miR-181b-5p levels at 1 year, but not at baseline, were higher in patients that developed ascites. The AUC of miR-181b-5p at 1 year to predict ascites was 0.7 (95% CI 0.59-0.78). miR-429 levels were lower at baseline in acute HVPG responders to NSBBs (AUC 0.65; 95% CI, 0.53-0.76), but levels at baseline and at 1 year were not associated with the HVPG response to NSBBs at 1 year. Conclusions: Serum miR-181b-5p is a promising non-invasive biomarker to identify patients with compensated cirrhosis at risk of ascites development. Lay summary: Ascites marks the transition from the compensated to decompensated stage in cirrhosis and indicates a worsening in prognosis. There are currently no easily accessible tools to identify patients with compensated cirrhosis at risk of developing ascites. We evaluated the levels of novel molecules termed microRNAs in the blood of patients with compensated cirrhosis and observed that miR-181b-5p can predict which patients are going to develop ascites.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/270216
https://dx.doi.org/urn:doi:10.1016/j.jhepr.2021.100368
url https://ddd.uab.cat/record/270216
https://dx.doi.org/urn:doi:10.1016/j.jhepr.2021.100368
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 SAF2017-86343-R
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI20/01302
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/01901
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 CIBEREHD-16PI03
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI20/00220
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 CM18/00091
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410826283122688
score 15,300719